JACOB J. KAHN · BOARD DIRECTOR · BOSTON, MASSACHUSETTS

Conflict of interest disclosure

Jacob J. Kahn holds investments in Phoenix Fund I (formerly known as HBS Phoenix Fund), owns public equity that he does not vote, is a member of HBS Angels of Boston and receives deal flow by email. This page states these interests and how he manages them.

Last updated October 31, 2026

Investment in Phoenix Fund I (formerly known as HBS Phoenix Fund)

Jacob J. Kahn holds investments in Phoenix Fund I (formerly known as HBS Phoenix Fund). He is its General Partner (2023–present) and a fiduciary to the fund's limited partners.

The fund invests in early-stage companies, listed below. A conflict could arise if a portfolio company is a counterparty, competitor, supplier or customer of an organization whose board he serves or is considered for, or is party to a transaction that board must approve. In any such case he discloses the relationship to the chair before the matter is discussed.

Fund I portfolio companies

The list below has 175 companies. It was obtained from Fund I and is reproduced as Fund I supplied it, grouped by the stage at which the fund invested, using Fund I's own stage labels. It has not been independently verified.

Pre-seed (49)

1kin.io · Aku · Anise Health · Apprenta · Arda · Astor · ByteKitchen · Candelytics · Cantant · CassVita · Circular Hospitality · Closing Theory · Concentro · Confido · DreamRP · Fiber AI · Figaro · Fluency · Frontrow Health · Garage Mobility · Green Room · Hue Beauty · Khibra · M7 Health · Modet · Nayak AI · Onboard · Otto · Parker · Ponte Labor · Prevent Biometrics · Privy · Reforged Labs · Revival Homes · Scorify Payments · SOAP Health · Spatio Metrics · Stealth Fintech · Stratagen Bio · Swerve · Syrup · The Goods · Thermaband · TimeCredit · Topset · Trove Health · Twenty · Voura · Zeph Technologies

Seed (106)

1stCollab · Agency · Agentic Labs · AiFlow · AKKO · Alfie · Appregator · Artos · AuraBlue · Autumn Labs (YC S24) · Basys · Be Golden · BoldVoice · Break Sports · Bunches · Callback (YC S24) · Canvas AI · Cheerfy · Cinapse · CodeComplete · Concord Materials · Condor · Deall! · Drumkit (fka Axle API) · Envel · Eqtble · Equipt Health · Fazeshift (YC S24) · Fluna · Front Edge · Givefront · Givz · Goodfin · Guardian Bio · Hazel · HeadsUp.ai · Imago Rehab · Invitris · Juicebox · Kiwi Biosciences / Fodzyme · Lagrange · Layup · Levee · Levro · Lime Therapeutics · Lion Pose · Lovage Labs · Lune · MagnaPlay · Marveri · Mederva Health · Minimum · Mooji Meats · Nephrogen · NextPlayU · Novig · Numida · Olive Legal (YC S24) · Orchid · Pando Bioscience · Penguin AI · PermitFlow · Pinnacle (YC S24) · Plenna · Pluria · Poka Labs (YC S24) · Poolit · PowerX · Praxos (YC S24) · PredictionStrike · Prohost AI (YC S24) · Promi (YC S24) · ProSights · Quaddro · Readlee (acq by Paper) · Relari · Reviving Mind · Rex · Rove · Ruuf · Salarybook · Science On Call · Serif Health · Serinus Biosciences · Shared Studios · Shekel Mobility · SilkChart · Smarty AI · Smoodi · Somn · Soteri Skin · Squack · Stairs Financial · Stealth Rollup · SustainFi · SynsoryBio · Taxo (YC S24) · Ten Lives · Tile · Topline Pro · Tornado · Trigo · True Footage · Upsolve AI · Vena Vitals · Zaymo

Seed-Ext (12)

Alariss · Boltive · Brij · Clarity Value · Factor · Homebase · IQBAR · NCL · OnRamp · Redbird · Seven Starling · Under the Doormat

Series A ("A") (4)

Dentologie · DynamiCare Health · Epicore Biosystems · Nomadica

Series B ("B") (3)

Boundless · Curebase · Raydiant Oximetry

"C plus" (1)

Stripe

HBS Angels of Boston and deal flow

Jacob J. Kahn is a member of HBS Angels of Boston. As a member he receives deal flow by email from various venture and private equity deals. Receiving a deal by email does not mean he has invested in it. Individual deals are not listed on this page.

Public equity

Jacob J. Kahn owns public equity. He does not vote it. This page does not list individual holdings or amounts. When he is considered for a board seat at a public company, he discloses any holding in that company, its competitors or its significant counterparties before the process continues.

How conflicts are managed

1. Disclose early. He gives this disclosure to the nominating and governance committee chair at the start of any candidacy and refreshes it at least once a year.
2. Disclose per matter. Before a board or committee discusses a Fund I portfolio company, or a company in which he owns public equity, he states the relationship.
3. Recuse. He steps out of deliberation and voting on any matter where a Fund I portfolio company is a counterparty or where the matter could affect the value of a holding.
4. Record it. He asks that the disclosure and any recusal be noted in the minutes.
5. Keep information separate. He does not use confidential board information in Fund I decisions or in trading public equity.

Questions a nominating committee may ask

Does he have a financial interest in companies that could deal with our company?

He holds investments in Fund I, which has 175 portfolio companies, listed above. Any overlap with the company's counterparties would be disclosed.

Does he own our stock?

He owns public equity. For any company he is considered for, he would disclose any holding before the process continues.

Does he vote the shares he owns?

No. He does not vote his public equity.

What happens if a conflict arises?

He discloses it, steps out of the discussion and vote, and asks that it be recorded in the minutes.

Does he see deals from other investors?

Yes. As a member of HBS Angels of Boston he receives deal flow by email from various venture and private equity deals.

Questions about this disclosure can be sent through the contact page.

Online version: **jacobjkahn.com/conflicts-of-interest/**